To examine putative relationships between adrenergic receptors on accessible circulating cells and relatively inaccessible extravascular catecholamine target tissues, we measured mononuclear leukocyte (MNL) and lung fl-adrenergic receptors and platelet and lung a-adrenergic receptors in tissues obtained from 15 patients undergoing pulmonary resection. Plasma catecholamine concentrations were measured concurrently to explore potential regulatory relationships between the activity of the sympathochromaffin system and both intravascular and extravascular adrenergic receptors. MNL and lung membrane 0-adrenergic receptor densities were correlated highly (r = 0.845, P < 0.001 The pharmacology, physiology, biochemistry, and cellular and molecular biology of the adrenergic receptors (adrenoceptors) that mediate the diverse actions of the catecholamines have been studied extensively in vitro and to a lesser extent in vivo in animals (1-3). Application of this data base to the study of adrenergic receptor regulation in humans is limited by the relative inaccessibility of relevant catecholamine target tissues such as heart, lung, etc. Therefore, most investigators studying human adrenergic receptors have measured these on accessible intravascular tissues, circulating mononuclear leukocytes (12-adrenergic receptors), platelets (a2-adrenergic receptors), or both, and used these measurements as indices of adrenergic receptor status on extravascular target tissues (3), i.e., those tissues that are not exposed directly to the intravascular compartment. This approach rests on the critical assumption that adrenergic receptor status on circulating cells reflects faithfully that on catecholamine target cells throughout the body. Although one can marshal a body of evidence to support this assumption, certain apparent exceptions led one of us to urge caution (4). For example, estrogen administration has been reported to decrease platelet but increase myometrial a-adrenergic receptor density in rabbits (5, 6), and thyroid hormone excess has been reported to increase human mononuclear leukocyte (7) and rat myocardial (8) fl-adrenergic receptor densities but decrease rat hepatic j3-adrenergic receptor density (9). Furthermore, regulation of extravascular adrenergic receptors by catecholamines has been found to be tissue and receptor subtype selective (10, 1 1). To our knowledge, the only published direct comparison ofadrenergic receptors on circulating and extravascular cells in humans is the report of Brodde et al. (12) that human myocardial and intact mononuclear leukocyte ,B-adrenergic receptor densities are correlated.
Introduction
To examine putative relationships between adrenergic receptors on accessible circulating cells and relatively inaccessible extravascular catecholamine target tissues, we measured mononuclear leukocyte (MNL) and lung fl-adrenergic receptors and platelet and lung a-adrenergic receptors in tissues obtained from 15 patients undergoing pulmonary resection. Plasma catecholamine concentrations were measured concurrently to explore potential regulatory relationships between the activity of the sympathochromaffin system and both intravascular and extravascular adrenergic receptors. MNL and lung membrane 0-adrenergic receptor densities were correlated highly (r = 0.845, P < 0.001). Platelet a2-adrenergic receptor and lung a1-adrenergic receptor densities were not. Lung a,-adrenergic receptor densities were positively related to plasma norepinephrine (r = 0.840, P < 0.01) and epinephrine (r = 0.860, P < 0.01) concentrations; in contrast, lung fl-adrenergic receptor densities were not positively related to plasma catecholamine concentrations (they tended to be inversely related to plasma norepinephrine and epinephrine [r = -0.698, P < 0.051 levels). This apparent reciprocal regulation of a-and fi-adrenergic receptors by the sympathochromafflin system was only demonstrable with adrenergic receptor measurements in the extravascular catecholamine target tissue. Neither MNL ,t-adrenergic receptor nor platelet a-adrenergic receptor densities were correlated with plasma catecholamine levels. Thus, although measurenients of f-adrenergic receptors on circulating mononuclear leukocytes can be used as indices of extravascular target tissue t-adrenergic receptor densities (at least in lung and heart), it would appear that extravascular tissues should be used to study adrenergic receptor regulation by endogenous catecholamines in humans. These data provide further support for the concept of up regulation, as well as down regulation, of some adrenergic receptor populations during short-term activation of the sympathochromaffin system in humans.
The pharmacology, physiology, biochemistry, and cellular and molecular biology of the adrenergic receptors (adrenoceptors) that mediate the diverse actions of the catecholamines have been studied extensively in vitro and to a lesser extent in vivo in animals (1) (2) (3) . Application of this data base to the study of adrenergic receptor regulation in humans is limited by the relative inaccessibility of relevant catecholamine target tissues such as heart, lung, etc. Therefore, most investigators studying human adrenergic receptors have measured these on accessible intravascular tissues, circulating mononuclear leukocytes (12- adrenergic receptors), platelets (a2-adrenergic receptors), or both, and used these measurements as indices of adrenergic receptor status on extravascular target tissues (3), i.e., those tissues that are not exposed directly to the intravascular compartment. This approach rests on the critical assumption that adrenergic receptor status on circulating cells reflects faithfully that on catecholamine target cells throughout the body. Although one can marshal a body of evidence to support this assumption, certain apparent exceptions led one of us to urge caution (4) . For example, estrogen administration has been reported to decrease platelet but increase myometrial a-adrenergic receptor density in rabbits (5, 6) , and thyroid hormone excess has been reported to increase human mononuclear leukocyte (7) and rat myocardial (8) fl-adrenergic receptor densities but decrease rat hepatic j3-adrenergic receptor density (9) . Furthermore, regulation of extravascular adrenergic receptors by catecholamines has been found to be tissue and receptor subtype selective (10, 1 1) . To our knowledge, the only published direct comparison ofadrenergic receptors on circulating and extravascular cells in humans is the report of Brodde et al. (12) that human myocardial and intact mononuclear leukocyte ,B-adrenergic receptor densities are correlated.
There is considerable evidence that catecholamines modulate adrenergic receptors (1) (2) (3) (4) . The most extensively studied pattern is an inverse relationship between agonist levels and adrenergic receptor function. For example, high catecholamine levels generally lead to desensitization of the tissue response to ,B-adrenergic agonists; among other possibilities, this involves uncoupling of,B-adrenergic receptors from adenylate cyclase, sequestration of the receptors from the cell surface into another plasma membrane or intracellular compartment, and an absolute decrease in the number of receptors (2) . Attempts to document these phenomena in humans have relied upon studies of adrenergic receptors on circulating cells; the results have not been clear cut. There is evidence that physiologic activation of the sympathochromaffin system and nor-epinephrine infusion are associated with uncoupling of leukocyte j3-adrenergic receptors (13, 14) . Sequestration of (-adrenergic receptors from the surface of leukocytes in response to increased endogenous catecholamine release in vivo has been difficult to demonstrate in humans (15) . An inverse relationship between endogenous plasma catecholamine concentrations and leukocyte fl-adrenergic receptor density in normal humans has been reported (14, 16) , but others have not found these to be correlated (7, 17, 18) . In patients with markedly elevated plasma catecholamine concentrations due to catecholamine-secreting pheochromocytomas, reduced leukocyte f3-adrenergic receptor density has been reported (19, 20) . Platelet a-adrenergic receptor density has not been found to be related to plasma catecholamine concentrations in normal humans (21, 22) and has been reported to be normal (20, 23) or decreased (19, 24) in patients with pheochromocytomas. Do these seemingly contradictory data indicate that adrenergic receptor down regulation by endogenous catecholamines is of little physiologic relevance in humans, or do they reflect limited utility of the use of adrenergic receptors on intravascular circulating cells as indices of the regulation of adrenergic receptors on extravascular catecholamine target tissues by the sympathochromaffin system?
In contrast to desensitization, there is some evidence that catecholamines may up regulate adrenergic receptors in humans. For example, mononuclear leukocyte fl-adrenergic receptor densities have been reported to increase initially during infusions of the agonists isoproterenol and epinephrine (25, 26) and during exercise (27, 28) . The interpretation of the latter data (25-28) is difficult, however, since one cannot be certain that the populations ofcells examined were not altered by the interventions. There is, to our knowledge, no precedent for agonist-induced up regulation of a-adrenergic receptors.
To examine the putative relationships between adrenergic receptors on circulating cells and those on an additional human extravascular catecholamine target tissue, we quantitated mononuclear leukocyte and lung fl-adrenergic receptors and platelet and lung a-adrenergic receptors in tissues obtained from patients undergoing pulmonary resection. Plasma catecholamine concentrations were measured concurrently to explore potential regulatory relationships between the activity of the sympathochromaffin (sympathoadrenal) system and both intravascular and extravascular adrenergic receptors.
Methods
Subjects. 15 35 ,000 g for 15 min and resuspension, followed by centrifugation at 400 g for 15 min. The membrane-rich supernatant contained < 2% ofthe original number of intact cells and was stored in 50 mM Tris and 10 mM MgCI2 buffer at -700C.
Platelet membranes were prepared as described previously (17) except that the Polytron was used for homogenization instead of a motor-driven mortar and pestle. Storage was at -70'C in 50 mM Tris, 10 mM MgCl2, and 5 mM EDTA buffer. Receptor binding studies. Assay conditions as described below provided the appropriate properties for ligand-receptor interactions (saturability, reversibility, stereospecificity, rank order potency and typical kinetics). In saturation binding studies, the concentration of unlabeled competitor used to determine nonspecific binding was 100 times the Ki as determined from competition experiments. Radioligand binding to membranes or intact cells was < 10% ofthat added to the reaction mixture. Guanosine triphosphate (GTP) (100 gM) was included in the ,-and a2-adrenergic receptor membrane studies to minimize retained catecholamine binding and to inhibit the accumulation of the ternary complex. When catecholamines were used as competitors, oxidation protection was afforded by 1.1 mM ascorbic acid for membrane studies, or 20 ,ug/ml each of superoxide dismutase and catalase for intact MNL studies (29) . Protein concentration was determined by the copper-bicinchoninic acid method (30) using bovine serum albumin standards, and cell counts were obtained from an automated cell counter (model S plus IV; Coulter Electronics, Hialeah, FL). After incubation for the specified times, the reactions were terminated by the addition of excess buffer, and the contents filtered over Whatman GF/C glass fiber filters (Whatman International, Maidstone, UK). The tubes and filters were then washed with additional buffer. In studies of intact MNL, a 5-min incubation with excess cold hypotonic PBS was used before filtering (see below). In experiments 1 . Abbreviations used in this paper: Bm.,, receptor density; CYP, cyanopindolol; DMEH, DME with 25 mM Hepes; ISO, isoproterenol; MNL, mononuclear leukocytes; PIN, pindolol; PLT, platelet; PRP, propranolol; PRZ, prazosin; YOH, yohimbine.
Lung Adrenergic Receptors 49 with1251-pindolol ('25I-PIN) the wet filters were counted in a gamma counter for I min. In studies with tritiated ligands filters were dried and then counted for 5 min in vials containing scintillation cocktail (3a70;
Research Products International, Mt. Prospect, IL). The decay of the 251 moiety of '25I-PIN was assumed to be catastrophic as described by Doyle, Buhler, and Burgisser (31) . Thus, with decay it is assumed that the binding properties of the pindolol are altered such that it does not bind to fl-adrenergic receptors with high affinity. Therefore, the "decay factor" is 1.0 regardless of the age of the ligand and increasing amounts of stock preparation are required to obtain the same concentration of labeled pindolol as the ligand ages. We confirmed this phenomenon by performing saturation binding studies on stock canine lung membranes using1251-PIN 1 d and 4 wk after iodination. During the study ofhuman tissues, a fresh batch of '251-PIN was obtained every 4 wk and fl-adrenergic receptor assays on samples from any given patient were performed within 3 d of each other.
TheBma,, (receptor density) and Kd (apparent dissociation constant) from saturation binding studies were derived by the method of Scatchard (32 For the current study, saturation binding experiments on cells harvested at 40C, as described above, were performed by incubating 2-5 X I.05 cells with eight concentrations of'25I-PIN (5-400 pM) alone and in the presence of PRP (10-6 M) and in the presence of CGP (10-6 M) in DMEH for 40 h at 40C. Preliminary studies showed that this incubation period is required for binding to reach equilibrium with heavily desensitized cells. Prior to filtering, each tube was filled with 10 ml of ice-cold :10 PBS and incubated for 5 min at4VC, a procedure known to decrease nonspecific binding (35) . After filtering, the tubes and filters were washed with 20 ml of room temperature PBS.
Lung, MNL, and platelet membranes. f3-Adrenergic receptors of lung and MNL were studied with '25I-PIN using methods similar to those described for membrane preparations from other tissues (36) . Membranes (10-40 ,ug) were incubated with nine concentrations of '251I-PIN (10-400 pM for MNL and 10-500 pM for lung) at 370C for Catecholamine determinations. Plasma norepinephrine and epinephrine levels were determined as described previously (38) using a single isotope derivative (radioenzymatic) assay based on the conversion of these catecholamines to their 0-methyl derivatives in the presence of methyl-[3H]-S-adenosyl-l-methionine. The 
Results
Representative specific binding curves and Scatchard plots for human MNL and lung membrane fl-adrenergic receptors are shown in Fig. 1 (36) and skeletal muscle (40) nmol/liter for platelet a2-adrenergic receptors and 1.3±0.4 nmol/liter for lung a1-adrenergic receptors (data not shown).
Mean (±SE) plasma norepinephrine and epinephrine concentrations prior to induction of anesthesia (preinduction),10 min after induction of anesthesia (post-induction) and at the time of lung resection are listed in Table II . Mean norepinephrine levels were approximately fivefold above resting normal values and mean epinephrine levels were approximately sevenfold above resting normal values (44). However, there was considerable scatter in the catecholamine levels.
Mean mononuclearleukocyte, platelet, and lung adrenergic receptor densities are listed in Table1. As with the plasma catecholamine levels, there was considerable scatter in the data. Notably, despite markedly elevated plasma catecholamine concentrations, more than 90% of fl-adrenergic receptors measured in intact MNL were external, i.e., on the cell surface.
Because long-term propranolol or metaproterenol ingestion might conceivably alter adrenergic receptors, adrenergic receptor characteristics (TableI), relationships among adrenergic receptors (Table III) and between adrenergic receptors and plasma catecholamine levels (Tables IV and V) were determined both for the entire data set and after exclusion of data from patients taking these drugs.
Relationships among adrenergic receptor densities on MNL, PLT, and lung are listed in Table III . Circulating MNL and lung membrane ft-adrenergic receptor densities were correlated highly (r = 0.845, P < 0.001) as shown in Fig. 4 (46) in rats. They found parallel increments in lymphocyte, lung and heart f3-adrenergic receptor densities during administration of the antagonist propranolol. Parenthetically, the relationship between MNL and lung f,-adrenergic receptor density was unaltered when data from patients taking propranolol or metaproterenol were excluded in the present study. Thus, these data provide further support for the use of measurements of MNL ,3-adrenergic receptor density as an index of that in human lung, as well as in human heart (12) . It should be noted, however, that tissue-specific responses to some stimuli, such as hypoxia (47) and hypertension (48), have been reported in some animal studies. Furthermore, as discussed shortly, adrenergic receptor status on circulating cells did not reflect clearly the relationships with sympathochromaffin activity found with adrenergic receptor status on an extravascular tissue in the present study.
In contrast to the findings with fl-adrenergic receptors, a- (41, 50) . It should be emphasized that the use oftissue homogenates precluded precise anatomic localization of the receptors measured. In lung, a-and f3-adrenergic receptors are distributed in alveolar walls, blood vessels and airways (50, 51) . In homogenates from peripheral lung, analogous to the samples used in the present study, the fl-adrenergic receptors are largely from alveolar walls (50) and the a-adrenergic receptors from vascular smooth muscle (51) .
Despite elevated plasma norepinephrine and epinephrine concentrations during surgery, the vast majority (> 90%) of f-adrenergic receptors were found to be on the surface ofintact MNL in these patients. These data provide further evidence that physiologic activation of the sympathochromaffin system does not result in substantial sequestration of f-adrenergic receptors on circulating cells in humans (15) . However, the con- (20-30%) of internalization of MNL jl-adrenergic receptors in vitro is -5,000 pg/ml (15) , much higher than the circulating levels in our patients. Since postjunctional adrenergic receptors in innervated tissues are exposed to norepinephrine concentrations higher than those in the circulation, and the actual neurally derived norepinephrine concentrations at such receptors are not known with certainty, these data do not exclude categorically receptor sequestration away from the cell surface by sympathetic neural activation in innervated tissues.
These data also disclosed highly significant positive relationships between lung a1-adrenergic receptor density and plasma norepinephrine and epinephrine concentrations after induction of anesthesia and at the time of lung resection in vivo in humans. This finding appears to be at variance with a body ofpublished in vitro and animal studies. For example, in vitro studies with a variety of cultured cell lines have generally demonstrated a decrease in a1-adrenergic receptor density during exposure to agonist (52) . Furthermore, Insel and colleagues (10) found a 76% reduction in lung a1-adrenergic receptor density in rats with implanted pheochromocytomas and markedly elevated plasma catecholamine levels. Thus, our finding of apparent up-regulation of lung a,-adrenergic recep- (44) . Finally, a semantic issue warrants comment. In the preceding paragraphs we have referred to lung adrenergic receptor up-and down-regulation in relation to circulating catecholamine levels. These terms are used commonly to indicate increments and decrements, respectively, in the total number of cellular receptors (1-3). We measured plasma membrane, rather than whole cell, adrenergic receptor densities in lung tissue; any internalized receptors in the "light vesicles" would have been discarded in the preparation of the membrane fractions (58, 59) . Thus, we cannot distinguish differences in receptor distribution away from the plasma membrane from differences in the total number of cellular receptors. Nonetheless, we note our inability to demonstrate fl-adrenergic receptor internalization into intact MNL under in vivo conditions, as discussed earlier, and submit that it is plasma membrane receptors that are more relevant to the biologic responsiveness of the tissue.
In summary, the data presented demonstrate that MNL and lung fl-adrenergic receptor densities are correlated in However, the data suggest that extravascular tissues should be used to study adrenergic receptor regulation by endogenous catecholamines. Finally, these data provide further support for the concept of up-regulation, as well as down-regulation, of some adrenergic receptor populations during short-term activation of the sympathochromaffin system in humans.
